Henry Schein, Inc.
HealthcareNASDAQ:HSIC · NASDAQ Global Select
+$1.03 today
Vol 1.08M · Avg 1.38M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $398.0M +0.0% | $398.0M -4.3% | $416.0M -26.5% | $566.0M -14.3% | $660.5M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $311.0M +16.0% | $268.0M +20.7% | $222.0M +4.7% | $212.0M +1.2% | $209.5M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $5.0M +108.9% | -$56.0M | $0 +100.0% | -$61.0M -371.7% | -$12.9M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $0 -100.0% | $39.0M +0.0% | $39.0M -27.8% | $54.0M -30.8% | $78.0M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$48.0M -134.3% | $140.0M +159.8% | -$234.0M +16.7% | -$281.0M -42.5% | -$197.2M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$124.0M -139.4% | $315.0M +196.3% | -$327.0M -4571.4% | -$7.0M -268.2% | $4.2M | $592.6M | $1.3B | $626.2M |
| Inventory | -$95.0M -61.0% | -$59.0M -125.5% | $231.0M +283.3% | -$126.0M +57.3% | -$295.1M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $216.0M +232.5% | -$163.0M | $0 +100.0% | -$96.0M -213.3% | $84.7M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$45.0M -195.7% | $47.0M +134.1% | -$138.0M -165.4% | -$52.0M -674.0% | $9.1M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $46.0M -22.0% | $59.0M +3.5% | $57.0M -49.1% | $112.0M +495.2% | -$28.3M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $712.0M -16.0% | $848.0M +69.6% | $500.0M -16.9% | $602.0M -15.2% | $709.6M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$139.0M +25.7% | -$187.0M -27.2% | -$147.0M -53.1% | -$96.0M -21.5% | -$79.0M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | -$276.0M -20.0% | -$230.0M | $0 +100.0% | -$158.0M +71.8% | -$560.8M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 | $0 +100.0% | -$11.0M -50.3% | -$7.3M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 -100.0% | $4.0M | $0 -100.0% | $11.0M +50.3% | $7.3M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$10.0M +82.1% | -$56.0M +94.3% | -$988.0M -4390.9% | -$22.0M +41.2% | -$37.4M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$477.0M -10.9% | -$430.0M +62.1% | -$1.1B -311.2% | -$276.0M +59.2% | -$677.2M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $551.0M +191.5% | $189.0M -79.0% | $900.0M +247.5% | $259.0M +57.0% | $165.0M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $252.0M | $0 | $0 | $0 | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$850.0M -120.8% | -$385.0M -35.6% | -$284.0M +41.4% | -$485.0M -20.9% | -$401.0M | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$64.0M +79.6% | -$314.0M -469.4% | $85.0M +249.1% | -$57.0M +35.9% | -$89.0M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$111.0M +78.2% | -$510.0M -172.8% | $701.0M +322.5% | -$315.0M +5.4% | -$333.0M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | -$90.0M -309.3% | $43.0M +458.3% | -$12.0M +0.0% | -$12.0M -357.0% | -$2.6M | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $34.0M +169.4% | -$49.0M -190.7% | $54.0M +5500.0% | -$1.0M +99.7% | -$303.2M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $573.0M -13.3% | $661.0M +87.3% | $353.0M -30.2% | $506.0M -19.8% | $630.6M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
DaVita Inc.
NYSE:DVA
$13.40B
Globus Medical, Inc.
NYSE:GMED
$10.84B
Molina Healthcare, Inc.
NYSE:MOH
$10.43B
Masimo Corporation
NASDAQ:MASI
$9.42B
Halozyme Therapeutics, Inc.
NASDAQ:HALO
$8.24B
Bio-Rad Laboratories, Inc.
NYSE:BIO
$7.73B
AptarGroup, Inc.
NYSE:ATR
$7.51B
Grifols, S.A.
NASDAQ:GRFS
$6.46B
Avantor, Inc.
NYSE:AVTR
$6.41B
SEC Filings
Recent regulatory filings
No filings found.
Does HSIC generate free cash flow?
Henry Schein, Inc. (HSIC) generated $573.00M of free cash flow in fiscal 2025.
How much operating cash flow does HSIC produce?
Operating cash flow was $712.00M, before capital expenditures of $139.00M.
Explore More
Continue the stock analysis
Jump to another research area for this company.